Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $10.00

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its target price lifted by LADENBURG THALM/SH SH from $4.00 to $10.00 in a research report released on Tuesday morning, The Fly reports. A number of other equities analysts also recently commented on CRVS. Mizuho restated a neutral rating and issued a $3.50 target price on shares of […]

Related Keywords

,Corvus Pharmaceuticals Stock Performance ,Corvus Pharmaceuticals Company Profile ,News Ratings For Corvus Pharmaceuticals Daily ,Discovery Capital Management ,Corvus Pharmaceuticals ,Cantor Fitzgerald ,Renaissance Technologies ,Corvus Pharmaceuticals Inc ,Institutional Trading Of Corvus Pharmaceuticals ,Get Rating ,Capital Management ,Sigma Advisers ,Sigma Investments ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Boost Price Target ,Ladenburg Thalm Sh ,